Pharmaceuticals company Zydus Lifesciences announced Q1FY25 results: Total revenues grew 21% YoY to Rs 62,075 million, led by growth across businesses. India branded formulations business posted double-digit growth and outpaced the market growth both in the chronic and acute segments. Consumer Wellness business delivered an industry leading double-digit growth aided by improved demand scenario and extended summer. US formulations business registered a robust sequential and y-o-y growth driven by new launches and volume expansion in base portfolio. On the international markets front, demand scenario remained strong across key markets and drove the growth. EBITDA margin stood at 33.6%, up 430 bps YoY. Capex (organic) for the quarter: Rs 3,014 million. Net cash: Rs 18,922 million (at 30-Jun’24) vs 8,561 million (at 31-Mar’24) Result PDF
Pharmaceuticals company Zydus Lifesciences announced Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Revenue from operations was Rs 55,338 million, up 10% over last year. Research & Development (R&D;) investments for the quarter stood at Rs 3,516 million (6.4% of revenues). EBITDA for the quarter was Rs 16,305 million, up 30% YoY. EBITDA margin for the quarter stood at 29.5%, an improvement of 440 bps on a YoY basis. Net Profit for the quarter was Rs 11,823 million, up 299% YoY. Capex (organic) for the quarter was Rs 2,126 million FY24 Financial Highlights: Revenue from operations was Rs 1,95,474 million, up 13% over last year. Research & Development (R&D;) investments stood at Rs 13,096 million (6.7% of revenues). EBITDA was Rs 53,843 million, up 40% YoY. EBITDA margin stood at 27.5%, an improvement of 510 bps over the previous year. Net Profit was Rs 38,595 million, up 97% YoY. Capex (organic) for the year was Rs 8,628 million. Net Debt to Equity ratio as on 31st March, 2024 was -0.04x while Net Debt to EBITDA stood at -0.16x at the end of March, 2024. Net Cash (negative Net Debt) as on March 31st, 2024 was Rs 8,561 million. Dr. Sharvil Patel, Managing Director, said, "We are happy to close the year on a strong note, driven by robust performance across our businesses. Our relentless focus on patient centricity, operational efficiency, strategic investments, and execution of our diversified product portfolio continues to pay off, resulting in a significant improvement in profitability as well. We aspire to sustain strong performance in fiscal year 2024-25 with strong revenue growth and strive to improve EBITDA margins further from FY24 levels. This strong performance is a testament to our commitment to creating long-term value for our stakeholders, and we are wellpositioned for future growth and innovation" Result PDF